CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤患者生育力的评估与保存
英文原题：Evaluation and preservation of fertility in patients with hematologic malignancies.
查看英文原题
Evaluation and preservation of fertility in patients with hematologic malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对于血液系统恶性肿瘤患者，新型治疗策略有望实现完全临床缓解和长期生存。然而，生育能力下降已成为一个重大问题，影响长期生活质量。已知传统高剂量化疗和放疗会降低生育能力或导致不育。此外，关于新型疗法，如靶向治疗和 CAR-T 细胞疗法，对生育能力影响的临床数据有限。再者，这些患者尚无保留生育能力的标准方法。男性患者可选择精子冷冻保存，而女性患者可通过胚胎、卵母细胞或卵巢组织冷冻保存来保留生育能力。然而，青春期前患者保留生育能力仍然特别具有挑战性。因此，血液科医生必须向患者告知癌症治疗可能产生的性腺毒性，并提供最合适的生育力保存选择。
展开英文摘要原文
For patients with hematologic malignancies, novel therapeutic strategies offer the potential to achieve a complete clinical response and long-term survival.
However, declining fertility has become a significant concern, impacting long-term quality of life. Conventional high-dose chemotherapy and radiotherapy are known to reduce fertility or cause sterility.
Moreover, limited clinical data are available on the effects of newer therapies, such as targeted treatments and chimeric antigen receptor (CAR)-T cell therapy, on fertility.
Additionally, there is no standard method for preserving fertility in these patients. Male patients can opt for sperm cryopreservation, whereas female patients may preserve fertility through embryo, oocyte, or ovarian tissue cryopreservation.
However, preserving fertility in prepubescent patients remains particularly challenging.
Therefore, hematologists must educate patients about the potential gonadal toxicity of cancer treatments and offer the most appropriate fertility preservation options.
论文信息
- 作者
- Wang X、Huang R、Liu L、Wang X、Zhang X
- 第一作者单位
- Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China; Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, 400037, China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, 400037, China; Jinfeng Laboratory, Chongqing, 400037, China.China
- 通讯作者单位
- Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China; Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China; Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, 400037, China; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, 400037, China; Jinfeng Laboratory, Chongqing, 400037, China. Electronic address: zhangxi@tmmu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Cancer letters2025 Apr 28
- 原文标识
- PubMed 39983893 · DOI 10.1016/j.canlet.2025.217569